Akari Therapeutics Reports Q1 2025 Financial Results

Akari Therapeutics PLC (ADR) ( (AKTX) ) has released its Q1 earnings. Here is a breakdown of the information Akari Therapeutics PLC (ADR) presented to its investors.

Akari Therapeutics PLC, a biotechnology company based in the United Kingdom, is focused on developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. The company’s recent earnings report highlights its ongoing efforts in research and development, particularly following its acquisition of Peak Bio, Inc. in November 2024. Akari reported a net loss of $3.7 million for the first quarter of 2025, a decrease from the $5.6 million loss in the same period the previous year. This reduction in loss is attributed to a decrease in operating expenses, notably in research and development and general administrative costs. The company also raised approximately $6.6 million through a private placement in March 2025, which included participation from its board members. Looking ahead, Akari remains focused on advancing its ADC platform and pipeline, with management actively exploring additional funding strategies to support its operations and research initiatives.